Project Grant F30CA281040
Award Date
8/7/24
Completion Date
1/31/26
Dollars Obligated
$161K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to enhance the efficacy of non-activated chimeric antigen receptor (CAR) T cell therapies for cancer treatment. The $587,108 award, with a period of performance from August 1, 2024 to July 31, 2029, will be conducted by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The key objectives of this research...
This Project Grant award of $406,249 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) was awarded to The Trustees of the University of Pennsylvania on September 18, 2024. The funding supports research to understand the barriers faced by chimeric antigen receptor (CAR) T cell therapy in treating solid tumors. The principal investigator, Dr. Andrew J. Rech, will apply a spatial multi-omic analytical platform to analyze tissue samples from five CAR T...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at understanding and engineering durable chimeric antigen receptor (CAR) T-cell therapies for solid tumor cancers. The key focus is on deconvolving the heterogeneity of CAR T-cell populations to identify strategies for programming optimal effector and memory T-cell responses. The research will utilize...
The National Institutes of Health (NIH) Office of the Director awarded a $1,602,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant, effective September 1, 2024 through August 31, 2027, aims to develop and optimize a new class of Epigenetic Reprogramming Factors (ERFs) to enhance the fitness of Chimeric Antigen Receptor (CAR) T cells for improved treatment of both liquid and solid tumors. The...
This $1,271,780 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pittsburgh to develop small molecule adaptors for precisely controlling universal chimeric antigen receptor (CAR) T cell therapies. The key objectives are to: Create small molecule adaptors that can target universal CAR T cells to multiple antigens, including on both tumor cells and immunosuppressive cells, to enhance therapeutic specificity....
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), will support research to dissect the intrinsic variability in engineered T cell immunotherapies. The $330,942 award to Stanford University, beginning September 1, 2024, aims to develop scalable screening methodologies to rapidly assess approved and proposed cellular immunotherapy constructs across a large number of cancer patients. The research will also explore...
The National Institutes of Health Office of the Director awarded a $2,925,000 Project Grant to The Trustees of the University of Pennsylvania under the Trans-NIH Research Support program (CFDA 93.310) on September 1, 2022 for a three-year period ending August 31, 2025. The grant will fund research to develop an in-depth understanding of transcriptional and epigenetic reprogramming of neutrophils in the tumor microenvironment. The grantee will leverage single-cell profiling, fate mapping, and...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports the development of an independent research program focused on evaluating novel cellular therapies to improve outcomes for pediatric patients with high-risk malignancies. The $289,458 award over 5 years (9/1/2024 - 8/31/2029) will enable the principal investigator to: Conduct a Phase I clinical trial evaluating an allogeneic CD19-CAR T-cell product using...
This $248,509 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by The Children's Hospital of Philadelphia (CHOP) to better understand the pathophysiology of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) - severe side effects that can occur with chimeric antigen receptor T-cell (CAR-T) cancer therapies. The key objectives are to: 1) Identify the cellular and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,856 to The Trustees of Columbia University in the City of New York, Health Sciences Division, for a project titled "Dissecting the Impact of Genomic Variants on Hallmarks of T Cell Anti-Tumor Activity". The project aims to perform in-depth mechanistic and in vivo functional studies of single-nucleotide variants (SNVs) in T cell signaling genes, including PIK3CD and PPP3CA,...